DEPLOYDatabase

Company

Zimmer Biomet

Zimmer Biomet, American orthopedic medical device company developing robotic surgery platforms ( Rosa) for joint replacement surgery.

Track Zimmer BiometGet notified of verified changes
HQ
Warsaw, IN
Status
public (NYSE: ZBH)
Models
1

Verified profile

  • 3

    Sources on record

  • 1

    Tracked changes

  • Updated 29 days ago

    Last verified change

Key facts

Product

ROSA robotic surgical assistant (Knee/Hip/Brain/Shoulder); cross-domain ortho + neuro.

Boundary

AI-augmented surgeon-controlled assistance, NOT autonomous (autonomy is the separate Monogram line).

Stock listing

NYSE: ZBH

ROSA origin

ROSA originated at Medtech SA

Acquisition year

Medtech SA acquired in 2016

Deploy Watch

Track Zimmer Biomet on Deploy.

We notify you when a verified state change lands on the record, not when the company issues a claim.

Data & sources

  • Press releases2
  • Web sources1

3 sources backing this record.View all →

Current platform

ROSA

ROSA, the Robotic Surgical Assistant, is Zimmer Biomet's surgeon-controlled robotic-arm platform, recorded in the surgical form factor as the mid-size, multi-procedure archetype of the orthopedic sub-cohort and the one that crosses surgical sub-domains, spanning orthopedics and neurosurgery from a single robotic-arm and navigation architecture. The arm is coupled to optical navigation and two- and three-dimensional planning software and positions or guides instruments, but it moves only on surgeon command and does not cut or place autonomously, so ROSA is AI-augmented surgeon-controlled assistance rather than autonomous surgery and is in scope as a surgical robot. Made by Zimmer Biomet Holdings, listed on the New York Stock Exchange as ZBH and headquartered in Warsaw, Indiana, ROSA originated at the French company Medtech SA, founded in 2002 in Montpellier by Bertin Nahum, which built ROSA Brain and ROSA Spine; Zimmer Biomet acquired Medtech SA in 2016 at fifty euros per share and extended the ROSA arm into orthopedics. The current Zimmer Biomet variants are ROSA Knee for total knee arthroplasty, cleared January 25, 2019 and enhanced as ROSA Knee with OptimiZe cleared November 14, 2025, ROSA Hip for direct anterior total hip arthroplasty cleared August 18, 2021, ROSA ONE Brain for cranial neurosurgery including biopsy, stereo-electro-encephalography, deep brain stimulation, and ventricular and transnasal endoscopy cleared February 11, 2019, and ROSA Shoulder for shoulder arthroplasty cleared in February 2024. ROSA ONE Spine, cleared in 2019, left Zimmer Biomet in the March 2022 ZimVie spinoff and is no longer a Zimmer Biomet product. A registry nuance worth recording is that autonomy enters Zimmer Biomet's portfolio separately through its Monogram Technologies acquisition, completed October 7, 2025, which brings a CT-based semi-autonomous total-knee robot and a fully-autonomous version in development; this is kept distinct from ROSA, whose surgeon-controlled status is unchanged. Installed-base figures circulating in aggregators conflict and none is asserted here.

surgicalView model →

Relationships

PPeritasAITechnology partner

Current leadership (2)

Board (1)

Former / Previously (1)

  • Greg Roche Global President, Robotics & Technologysecondary-verified

Safety record

12 recalls and 3 incidents on record (1 catastrophic, 2 critical, 12 serious). Most recent: Jun 2026.

catastrophic
1
critical
2
serious
12
recall
12
malfunction
2
injury
1

Most recent: Jun 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Incidents affecting Zimmer Biomet (15)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Recent coverage

Zimmer Biomet in third-party press

Peer companies